Video Series

Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.

Sergio A. Giralt, MD, discusses the key results from recent chronic graft-vs-host disease (cGVHD) research presented at ASH 2024 and how these findings will influence his clinical practice. He also shares his main takeaways on evolving strategies for cGVHD management.

Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective. He reviews the study design and methods of recent research investigating cyclophosphamide in cGVHD management, emphasizing its importance in optimizing treatment strategies.

Sergio A. Giralt, MD, discusses how he selects patients with chronic graft-vs-host disease (cGVHD) for treatment with ruxolitinib, often in combination with corticosteroids, and reviews the study design and methods of recent research on ruxolitinib in cGVHD management, highlighting key efficacy and safety results and how these findings align with his clinical practice.

Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the study design and efficacy and safety data from recent trials and discusses how these results will influence his clinical practice moving forward.

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions. Definitive diagnosis requires molecular and immunological testing of stool samples to detect toxin genes and active toxin production.

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource utilization while severely compromising patient quality of life through persistent physical symptoms, psychological distress, and substantial social disruptions.

Panelists discuss how they assess the individual support needs of patients diagnosed with diffuse large B-cell lymphoma or follicular lymphoma and describe an ideal model for industry-provided support services for these patients.

Panelist discusses how social determinants of health create significant diagnostic barriers for hidradenitis suppurativa through systemic inequities, limited health care access, and provider knowledge gaps. Health systems can mitigate these challenges through targeted educational, technological, and culturally responsive interventions.

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world factors influencing treatment decisions, highlighting the significant role of survivorship burden and patient preferences, and emphasizing how these findings should shape the management strategies for patients with multiple myeloma.

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.

Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.

Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.

Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD) as a biomarker across various treatment settings and clinical trials to ensure consistent and reliable use in treatment decision-making.

Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the role of MRD as a biomarker in multiple myeloma treatment, highlighting its potential to guide therapy decisions and improve patient outcomes.

Panelists discuss how iron deficiency anemia manifests through debilitating symptoms, including severe fatigue, weakness, shortness of breath, headaches, and difficulty concentrating, which can profoundly impact patients’ daily functioning, work performance, and overall quality of life.

Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and psychological support strategies employed to help patients navigate their lymphoma journey.

A panelist discusses how digital patient engagement tools and collaboration with advocacy groups can enhance treatment adherence and care coordination while providing vital support and resources for individuals managing Lambert-Eaton myasthenic syndrome (LEMS).

Dr. Bijal Shah shares insights on anticipated updates to NCCN guidelines for Ph+ ALL, emphasizing key areas of focus to address gaps and advance patient care.

Robert M. Rifkin, MD, FACP, discusses how the MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition sheds light on elranatamab’s role in relapsed/refractory multiple myeloma while panelists discuss how emerging data on bispecific antibodies and combination strategies could shape treatment timing and improve outcomes, especially in heavily pretreated patients.

Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production. Characterized by repeated episodes of colitis, it predominantly affects older, hospitalized patients with compromised immune systems, presenting significant clinical challenges through inflammatory complications and potential systemic spread.

The panelist discusses how early detection of recurrent Clostridioides difficile infections is critical in clinical practice because these infections can rapidly escalate patient morbidity and mortality. Recurrent C difficile infections are associated with significantly increased mortality rates, with studies showing that patients experiencing multiple infection episodes have a higher risk of complications, prolonged hospital stays, and increased health care costs. Early identification allows for prompt intervention, which can help prevent disease progression, reduce transmission risks, and implement targeted treatment strategies.

A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton myasthenic syndrome (LEMS) patients, particularly those with dual diagnoses like small cell lung cancer (SCLC), while ensuring both clinical effectiveness and cost-efficiency through managed care strategies.

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Prospective Patient Preference Study for BTKi Treatment Attributes in CLL and SLL” explored the factors influencing patient decision-making, revealing key treatment preferences and highlighting the importance of incorporating these insights into clinical practice when selecting BTK inhibitors for patients with CLL or SLL.

Wendy Cheng, PhD, MPH, discusses how the study on the efficacy of gepotidacin vs nitrofurantoin in a nitrofurantoin-resistant population (a pooled analysis of the EAGLE-2 and EAGLE-3 trials) aimed to evaluate the effectiveness of gepotidacin as a first-in-class oral therapy for uncomplicated urinary tract infections (uUTIs), showing promising results in overcoming antimicrobial resistance and potentially filling critical gaps in current UTI treatments.

Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.

Panelists discuss how iron deficiency anemia significantly impacts patients’ quality of life through symptoms like chronic fatigue, shortness of breath, and cognitive dysfunction, while also creating substantial psychosocial burdens including depression, reduced work productivity, and social isolation, particularly affecting vulnerable populations who may face barriers to diagnosis and treatment.

Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, highlighting its safety profile and 100% minimal residual disease (MRD) negativity after cycle 3, and explores how using bispecific antibodies like teclistamab earlier in treatment could influence future options for relapsed/refractory multiple myeloma.

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi) trials in chronic lymphocytic leukemia (CLL) are addressing unmet needs by offering new treatment options that target treatment-naive patients, potentially improving outcomes and filling gaps in the current therapeutic landscape.